PHARMACOKINETICS, PHARMACODYNAMICS, EFFICACY AND SAFETY OF RAVULIZUMAB IN CHILDREN AND ADOLESCENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: INTERIM ANALYSIS OF A PHASE 3, OPEN-LABEL STUDY
EHA Library, Satheesh Chonat,
325350
OTHER MALIGNANCIES IN THE HISTORY OF CHRONIC LYMPHOCYTIC LEUKEMIA – A RETROSPECTIVE, MULTICENTER COHORT STUDY BY ERIC, THE EUROPEAN RESEARCH INITIATIVE ON CLL, IN HARMONY
EHA Library, Thomas Chatzikonstantinou,
325391
PIRTOBRUTINIB (LOXO-305), A NEXT GENERATION, HIGHLY SELECTIVE, NON-COVALENT BTK INHIBITOR IN PREVIOUSLY TREATED CLL/SLL: RESULTS FROM THE PHASE 1/2 BRUIN STUDY
EHA Library, Lindsey Roeker,
325393
TG-1701, A SELECTIVE BRUTON TYROSINE KINASE (BTK) INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH UBLITUXIMAB AND UMBRALISIB (U2) IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND LYMPHOMA
EHA Library, Chan Y. Cheah,
325398
MOLTO, A MULTICENTER, OPEN LABEL, UNCONTROLLED, PHASE II CLINICAL TRIAL ON SAFETY AND EFFICACY OF VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB IN RICHTER TRANSFORMATION OF CLL: SAFETY INTERIM ANALYSIS
EHA Library, Anna Maria Frustaci,
325410
BCX9930, A NOVEL ORAL FACTOR D INHIBITOR, HAS POSITIVE EFFECTS ON HEMOLYSIS AND CLINICAL OUTCOMES IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) NAÏVE TO COMPLEMENT INHIBITORS
EHA Library, Andrew McDonald,
325345
BCX9930, AN ORAL FACTOR D INHIBITOR, CONTROLS EXTRAVASCULAR HEMOLYSIS AND ALLEVIATES ASSOCIATED SYMPTOMS IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA INADEQUATELY CONTROLLED ON C5 INHIBITORS
EHA Library, Austin Kulasekararaj,
325349